Overview

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Status:
RECRUITING

Trial end date:
2026-01-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator:

SupermAb (BeiJing) Biotech Co., Ltd